{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T08:52:40Z","timestamp":1783759960066,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-024-01375-5","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T12:02:04Z","timestamp":1727438524000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Thoracic epithelioid inflammatory myofibroblastic sarcoma: a rare and aggressive disease with case report and literature review"],"prefix":"10.1007","volume":"15","author":[{"given":"Linke","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runze","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baomin","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqing","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangjian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,27]]},"reference":[{"issue":"6","key":"1375_CR1","first-page":"9317","volume":"15","author":"X Du","year":"2018","unstructured":"Du X, Gao Y, Zhao H, Li B, Xue W, Wang D. Clinicopathological analysis of epithelioid inflammatory myofibroblastic sarcoma. Oncol Lett. 2018;15(6):9317\u201326.","journal-title":"Oncol Lett"},{"issue":"1","key":"1375_CR2","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1097\/PAS.0b013e318200cfd5","volume":"35","author":"A Mari\u00f1o-Enr\u00edquez","year":"2011","unstructured":"Mari\u00f1o-Enr\u00edquez A, Wang WL, Roy A, Lopez-Terrada D, Lazar AJ, Fletcher CD, et al. Epithelioid inflammatory myofibroblastic sarcoma: an aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK. Am J Surg Pathol. 2011;35(1):135\u201344.","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"1375_CR3","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/path.4836","volume":"241","author":"JC Lee","year":"2017","unstructured":"Lee JC, Li CF, Huang HY, Zhu MJ, Mari\u00f1o-Enr\u00edquez A, Lee CT, et al. ALK oncoproteins in atypical inflammatory myofibroblastic tumours: novel RRBP1-ALK fusions in epithelioid inflammatory myofibroblastic sarcoma. J Pathol. 2017;241(3):316\u201323.","journal-title":"J Pathol"},{"issue":"37","key":"1375_CR4","doi-asserted-by":"publisher","first-page":"13625","DOI":"10.3748\/wjg.v20.i37.13625","volume":"20","author":"JJ Zhao","year":"2014","unstructured":"Zhao JJ, Ling JQ, Fang Y, Gao XD, Shu P, Shen KT, et al. Intra-abdominal inflammatory myofibroblastic tumor: spontaneous regression. World J Gastroenterol. 2014;20(37):13625\u201331.","journal-title":"World J Gastroenterol"},{"key":"1375_CR5","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13000-015-0358-1","volume":"10","author":"X Fu","year":"2015","unstructured":"Fu X, Jiang J, Tian XY, Li Z. Pulmonary epithelioid inflammatory myofibroblastic sarcoma with multiple bone metastases: case report and review of literature. Diagn Pathol. 2015;10:106.","journal-title":"Diagn Pathol"},{"issue":"4","key":"1375_CR6","doi-asserted-by":"publisher","first-page":"231","DOI":"10.4132\/jptm.2022.05.08","volume":"56","author":"P Singh","year":"2022","unstructured":"Singh P, Nambirajan A, Gaur MK, Raj R, Kumar S, Malik PS, et al. Primary pulmonary epithelioid inflammatory myofibroblastic sarcoma: a rare entity and a literature review. J Pathol Transl Med. 2022;56(4):231\u20137.","journal-title":"J Pathol Transl Med"},{"issue":"10","key":"1375_CR7","first-page":"E513","volume":"7","author":"DE Sarmiento","year":"2015","unstructured":"Sarmiento DE, Clevenger JA, Masters GA, Bauer TL, Nam BT. Epithelioid inflammatory myofibroblastic sarcoma: a case report. J Thorac Dis. 2015;7(10):E513\u20136.","journal-title":"J Thorac Dis"},{"issue":"3","key":"1375_CR8","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s11748-013-0204-x","volume":"62","author":"Y Kozu","year":"2014","unstructured":"Kozu Y, Isaka M, Ohde Y, Takeuchi K, Nakajima T. Epithelioid inflammatory myofibroblastic sarcoma arising in the pleural cavity. Gen Thorac Cardiovasc Surg. 2014;62(3):191\u20134.","journal-title":"Gen Thorac Cardiovasc Surg"},{"issue":"8","key":"1375_CR9","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1002\/cncy.21558","volume":"123","author":"JC Lee","year":"2015","unstructured":"Lee JC, Wu JM, Liau JY, Huang HY, Lo CY, Jan IS, et al. Cytopathologic features of epithelioid inflammatory myofibroblastic sarcoma with correlation of histopathology, immunohistochemistry, and molecular cytogenetic analysis. Cancer Cytopathol. 2015;123(8):495\u2013504.","journal-title":"Cancer Cytopathol"},{"key":"1375_CR10","doi-asserted-by":"publisher","first-page":"117954762311639","DOI":"10.1177\/11795476231163954","volume":"16","author":"S Aminimoghaddam","year":"2023","unstructured":"Aminimoghaddam S, Pourali R. Epithelioid inflammatory myofibroblastic sarcoma with poor response to crizotinib: a case report. Clin Med Insights Case Rep. 2023;16:11795476231163954.","journal-title":"Clin Med Insights Case Rep"},{"key":"1375_CR11","doi-asserted-by":"publisher","first-page":"1084456","DOI":"10.3389\/fonc.2023.1084456","volume":"13","author":"M Li","year":"2023","unstructured":"Li M, Xing R, Huang J, Shi C, Wei C, Wang H. Case report: epithelioid inflammatory myofibroblastic sarcoma treated with an ALK TKI ensartinib. Front Oncol. 2023;13:1084456.","journal-title":"Front Oncol"},{"issue":"1","key":"1375_CR12","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1177\/1066896918767557","volume":"27","author":"M Hallin","year":"2019","unstructured":"Hallin M, Thway K. Epithelioid inflammatory myofibroblastic sarcoma. Int J Surg Pathol. 2019;27(1):69\u201371.","journal-title":"Int J Surg Pathol"},{"issue":"3","key":"1375_CR13","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.4143\/crt.2022.894","volume":"55","author":"X Liu","year":"2023","unstructured":"Liu X, Gong C, Zhang J, Feng W, Guo Y, Sang Y, et al. Clinicopathological analysis and treatment of adult patients with inflammatory myofibroblastic tumor: a 15-year single-center study. Cancer Res Treat. 2023;55(3):1001\u201310.","journal-title":"Cancer Res Treat"},{"key":"1375_CR14","doi-asserted-by":"publisher","first-page":"761558","DOI":"10.3389\/fonc.2022.761558","volume":"12","author":"Z Wang","year":"2022","unstructured":"Wang Z, Geng Y, Yuan LY, Wang MM, Ye CY, Sun L, et al. Durable clinical response to ALK tyrosine kinase inhibitors in epithelioid inflammatory myofibroblastic sarcoma harboring PRRC2B-ALK rearrangement: a case report. Front Oncol. 2022;12:761558.","journal-title":"Front Oncol"},{"issue":"1","key":"1375_CR15","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s10014-021-00416-z","volume":"39","author":"S Chopra","year":"2022","unstructured":"Chopra S, Maloney N, Wang WL. Epithelioid inflammatory myofibroblastic sarcoma with VCL-ALK fusion of central nervous system: case report and brief review of the literature. Brain Tumor Pathol. 2022;39(1):35\u201342.","journal-title":"Brain Tumor Pathol"},{"issue":"1","key":"1375_CR16","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13023-017-0647-8","volume":"12","author":"Q Jiang","year":"2017","unstructured":"Jiang Q, Tong HX, Hou YY, Zhang Y, Li JL, Zhou YH, et al. Identification of EML4-ALK as an alternative fusion gene in epithelioid inflammatory myofibroblastic sarcoma. Orphanet J Rare Dis. 2017;12(1):97.","journal-title":"Orphanet J Rare Dis"},{"key":"1375_CR17","first-page":"2370","volume":"17","author":"X Xu","year":"2019","unstructured":"Xu X, Li H, Peng K, Yu Y, Chen L, Fang Y, et al. ALK-G1269A mutation in epithelioid inflammatorymyofibroblastic sarcoma after progression on crizotinib: a case report. Oncol Lett. 2019;17:2370\u20136.","journal-title":"Oncol Lett"},{"issue":"19","key":"1375_CR18","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.2169\/internalmedicine.53.2546","volume":"53","author":"K Kurihara-Hosokawa","year":"2014","unstructured":"Kurihara-Hosokawa K, Kawasaki I, Tamai A, Yoshida Y, Yakushiji Y, Ueno H, et al. Epithelioid inflammatory myofibroblastic sarcoma responsive to surgery and an ALK inhibitor in a patient with panhypopituitarism. Intern Med. 2014;53(19):2211\u20134.","journal-title":"Intern Med"},{"issue":"18","key":"1375_CR19","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1056\/NEJMoa1007056","volume":"363","author":"JE Butrynski","year":"2010","unstructured":"Butrynski JE, D\u2019Adamo DR, Hornick JL, Dal Cin P, Antonescu CR, Jhanwar SC, et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med. 2010;363(18):1727\u201333.","journal-title":"N Engl J Med"},{"issue":"1","key":"1375_CR20","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13000-016-0517-z","volume":"11","author":"L Yu","year":"2016","unstructured":"Yu L, Liu J, Lao IW, Luo Z, Wang J. Epithelioid inflammatory myofibroblastic sarcoma: a clinicopathological, immunohistochemical and molecular cytogenetic analysis of five additional cases and review of the literature. Diagn Pathol. 2016;11(1):67.","journal-title":"Diagn Pathol"},{"issue":"9","key":"1375_CR21","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1093\/jjco\/hyu069","volume":"44","author":"S Kimbara","year":"2014","unstructured":"Kimbara S, Takeda K, Fukushima H, Inoue T, Okada H, Shibata Y, et al. A case report of epithelioid inflammatory myofibroblastic sarcoma with RANBP2-ALK fusion gene treated with the ALK inhibitor, crizotinib. Jpn J Clin Oncol. 2014;44(9):868\u201371.","journal-title":"Jpn J Clin Oncol"},{"key":"1375_CR22","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejca.2021.07.016","volume":"156","author":"P Schoffski","year":"2021","unstructured":"Schoffski P, Kubickova M, Wozniak A, Blay JY, Strauss SJ, Stacchiotti S, et al. Long-term efficacy update of crizotinib inpatients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE. Eur J Cancer. 2021;156:12\u201323.","journal-title":"Eur J Cancer"},{"issue":"11","key":"1375_CR23","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1093\/annonc\/mdw405","volume":"27","author":"AS Mansfield","year":"2016","unstructured":"Mansfield AS, Murphy SJ, Harris FR, Robinson SI, Marks RS, Johnson SH, et al. Chromoplectic TPM3-ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib. Ann Oncol. 2016;27(11):2111\u20137.","journal-title":"Ann Oncol"},{"issue":"12","key":"1375_CR24","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1016\/S1470-2045(21)00536-2","volume":"22","author":"M Fischer","year":"2021","unstructured":"Fischer M, Moreno L, Ziegler DS, Marshall LV, Zwaan CM, Irwin MS, et al. Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion study. Lancet Oncol. 2021;22(12):1764\u201376.","journal-title":"Lancet Oncol"},{"issue":"8","key":"1375_CR25","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","volume":"31","author":"T Mok","year":"2020","unstructured":"Mok T, Camidge DR, Gadgeel SM, Rosell R, Dziadziuszko R, Kim DW, et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol. 2020;31(8):1056\u201364.","journal-title":"Ann Oncol"},{"key":"1375_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.18.00297","volume":"3","author":"T Trahair","year":"2019","unstructured":"Trahair T, Gifford AJ, Fordham A, Mayoh C, Fadia M, Lukeis R, et al. Crizotinib and Surgery for long-term disease control in children and adolescents with ALK-positive inflammatory myofibroblastic tumors. JCO Precis Oncol. 2019;3:1-11.","journal-title":"JCO Precis Oncol"},{"issue":"4","key":"1375_CR27","first-page":"4213","volume":"8","author":"H Wu","year":"2015","unstructured":"Wu H, Meng YH, Lu P, Ning HY, Hong L, Kang XL, et al. Epithelioid inflammatory myofibroblastic sarcoma in abdominal cavity: a case report and review of literature. Int J Clin Exp Pathol. 2015;8(4):4213\u20139.","journal-title":"Int J Clin Exp Pathol"},{"issue":"4","key":"1375_CR28","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/DAD.0000000000002096","volume":"44","author":"L Gadeyne","year":"2022","unstructured":"Gadeyne L, Creytens D, Dekeyser S, Van der Meulen J, Haspeslagh M. Primary cutaneous epithelioid inflammatory myofibroblastic sarcoma harboring RANBP2-ALK fusion: report of an exceptional case. Am J Dermatopathol. 2022;44(4):302\u20135.","journal-title":"Am J Dermatopathol"},{"issue":"7","key":"1375_CR29","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1038\/s41416-020-0996-2","volume":"123","author":"AM Fordham","year":"2020","unstructured":"Fordham AM, Xie J, Gifford AJ, Wadham C, Morgan LT, Mould EVA, et al. CD30 and ALK combination therapy has high therapeutic potency in RANBP2-ALK-rearranged epithelioid inflammatory myofibroblastic sarcoma. Br J Cancer. 2020;123(7):1101\u201313.","journal-title":"Br J Cancer"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-024-01375-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-024-01375-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-024-01375-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T12:18:49Z","timestamp":1727439529000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-024-01375-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,27]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1375"],"URL":"https:\/\/doi.org\/10.1007\/s12672-024-01375-5","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,27]]},"assertion":[{"value":"25 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was granted an exemption from requiring ethics approval from the Ethics Committee of Shandong Cancer Hospital and Institute, as it was an observational report. All the human data was in accordance with the guidelines of the 1964 Declaration of Helsinki, and written informed consent for study participation from this patient was obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for the publication of this case report and any accompanying images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"484"}}